Article in eLife, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Youcai XiongCenter for Advanced Models for Translational Sciences and Therapeutics, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, United States.
Li-Kuang TsaiCenter for Advanced Models for Translational Sciences and Therapeutics, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, United States.
Jun ZhouCenter for Advanced Models for Translational Sciences and Therapeutics, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, United States.
Shuang ChenCenter for Advanced Models for Translational Sciences and Therapeutics, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, United States.
Xiaofeng XiaResearch & Development, ATGC Inc, King of Prussia, United States.
Jifeng ZhangCenter for Advanced Models for Translational Sciences and Therapeutics, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, United States.ORCID https://orcid.org/0000-0001-5161-4705
Y Eugene ChenCenter for Advanced Models for Translational Sciences and Therapeutics, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, United States.
Jie XuCenter for Advanced Models for Translational Sciences and Therapeutics, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, United States.
Xiaoqiang HuangCenter for Advanced Models for Translational Sciences and Therapeutics, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, United States.ORCID https://orcid.org/0000-0002-1005-848X
Funding
NIH HHS GM149016NIH HHS HL164205
6 · The paper itself
Abstract
CRISPR-Cas9 nucleases have transformed genome engineering, yet their application is often constrained by protospacer-adjacent motif (PAM) requirements.
Indexed as
CRISPR-Associated Protein 9CRISPR-Cas SystemsGene EditingStaphylococcus aureusCRISPR-Associated Protein 9base editingcomputational biologycomputational protein designCRISPR-Cas9genome editinghumanPAM relaxationSaCas9systems biology
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Fully computational design of PAM-relaxed · full record | OpenQuestion